by Gertrud U. Rey Almost sixty years have passed since the initial formalin-inactivated respiratory syncytial virus (RSV) vaccine caused enhanced disease in children when they were subsequently infected with the virus. Since then, RSV has continued to be a substantial public health threat to infants, young children, and older people. Although progress in developing a …
TWiV reviews the FDA decision to update COVID-19 vaccine boosters in the fall, the meaning of fatigue with respect to long COVID, and a skin volatile induced by flavivirus reproduction that attracts mosquitoes to the infected host.
On February 27, 2021, the FDA issued an emergency use authorization for a one-dose SARS-CoV-2 vaccine developed by Janssen Pharmaceutica, a Belgium-based division of Johnson & Johnson.
Daniel Griffin provides a clinical report on COVID-19, then former FDA Chief of Staff to the Commissioner Denise Esposito joins us to explain the challenges in approving vaccines, antiviral drugs, and diagnostic tests during a pandemic, followed by answers to listener questions. Click arrow to playDownload TWiV 651 (98 MB .mp3, 164 min)Subscribe (free): iTunes, Google Podcasts, RSS, email Become …
There have been many interesting responses to my recent post, “Are you receiving the influenza 2009 H1N1 vaccine?” Some individuals have already been immunized or plan to do so shortly. Others are concerned about the safety and efficacy of the monovalent preparations. As pointed out recently in a Nature editorial, “Mass-vaccination campaigns…must take public concerns …
Influenza A (H1N1) 2009 vaccine: efficacy and safety Read More »
The oral poliovirus vaccine strains (OPV) developed by Albert Sabin were licensed in the United States in 1962, and over the next 37 years immunization with these vaccines lead to the eradication of poliomyelitis in this country. During that period, the vaccine was responsible for 5-10 cases of poliomyelitis each year, either in recipients of …
